FINACEA (azelaic acid) by Leo Pharma is mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown. First approved in 2015.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
FINACEA (azelaic acid) is a topical foam approved in 2015 for the treatment of rosacea, a chronic inflammatory skin condition. The exact mechanism of action remains unclear, though the drug is believed to interfere with pathogenic pathways in rosacea. It is administered as a topical aerosol foam formulation.
With LOE approaching in 2.7 years and modest Part D spending of $2M, the brand team is likely in defensive mode managing market transition and preparing for generic entry.
mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma
Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea
Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study
Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris
Worked on FINACEA at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
FINACEA is a mature, niche dermatology product with minimal current job openings, reflecting its small market footprint ($2M Part D spend) and approaching loss of exclusivity. Working on this brand offers limited growth opportunity but valuable experience in defensive commercial strategy, patient access, and generic transition planning for pharma professionals early in their careers or seeking stable, specialized roles.